Post-graduate theses
Search command : Author="Κούτρα"
And Author="Αικατερίνη"
Current Record: 32 of 6578
|
Identifier |
000463831 |
Title |
Σαρκώματα μήτρας : Αντιμετώπιση και προγνωστικοί παράγοντες-Μια αναδρομική έρευνα ασθενών από ένα ελληνικό ογκολογικό κέντρο |
Alternative Title |
Uterine sarcomas |
Author
|
Στρατάκη, Καλλιόπη
|
Thesis advisor
|
Μαυρουδής, Δημήτριος
|
Reviewer
|
Παπαθεοδώρου, Δημήτριος
Βρεκούσης, Θωμάς
|
Abstract |
Uterine sarcomas
are a rare histologically heterogeneous group of tumors, which
is associated with an extremely poor prognosis. In the literature to date, there is no
agreement regarding the risk factors, the prognosis and the most effective treatment of
this aggressive group of mesenchymal tumors . T he purpose of this retrospective study is
to describe the experience of a Greek Cancer Hospital in the last decade as well as to
study possible factors influencing the prognosis of these aggressive neoplasms.
The "Agios Savvas" hospital is an anticancer
and oncological center in Athens,
with extensive experience in the management and treatment of oncological cases. From
the databases of the involved departments of the "Agios Savvas" hospital, all patients
with the diagnosis of uterine sarcoma, in the period 2010 2020, were searched and
analyzed. The research criteria included: age at diagnosis, histological type, grade of
differentiation, initial tumor size, metastatic extension of the disease, type of treatment ,
and finally disease progression, including data on disease recurrence and disease free
interval and overall patient survival by December 2023.
In our retrospective study, 28 cases were included, of which fourteen (14) had a
histological diagnosis of Leiomyosarcoma (LMS), seven (7) had a diagnosis of
Endometrial Stromal Sarcoma (ESS), six (6) had a diagnosis of Undifferentiated Uterine
Sarcoma (UU S) and there was one case with a diagnosis of Rhabdomyosarcoma. The
mean age at diagnosis was 57.3 years and the mean tumor size 8.7 cm. 57.2% of patients
were in Stage I at diagnosis, 10.7% of patients in Stage II, 3.6% of patients in Stage III
and 15% in Stage IV. Median overall survival (OS) was 42.8 months while median
disease free survival (DFS) for early stage patients was 30.3 months and median
progression free survival (PFS) for Stage IV patients was 2 1 months.
|
Language |
Greek, English |
Subject |
Disease free survival (DFS) |
|
High grade-endometrial stromal sarcomas (HG-ESS) |
|
Leiomyosarcoma (LMS) |
|
Low grade-endometrial stromal sarcomas (LG-ESS) |
|
Overal survival (OS) |
|
Progression free survival (PFS) |
|
Undifferentiated uterine sarcomas(UUS) |
|
Αδιαφοροποίητα σαρκώματα |
|
Επιβίωση ελευθέρας νόσου |
|
Επιβίωση χωρίς πρόοδο νόσου |
|
Λειομυοσαρκώματα |
|
Υψηλού βαθμού κακοήθειας στρωματικά σαρκώματα ενδομητρίου |
|
Χαμηλού βαθμού κακοήθειας στρωματικά σαρκώματα ενδομητρίου |
Issue date |
2024-04-17 |
Collection
|
School/Department--School of Medicine--Department of Medicine--Post-graduate theses
|
|
Type of Work--Post-graduate theses
|
Permanent Link |
https://elocus.lib.uoc.gr//dlib/b/3/2/metadata-dlib-1712916371-800225-834.tkl
|
Views |
7 |